Global Live Attenuated Influenza Vaccine Laiv Market Research Report 2025(Status and Outlook)
Description
Report Overview
A Live Attenuated Influenza Vaccine (LAIV), also known as the ""nasal spray"" or ""intranasal"" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
The global Live Attenuated Influenza Vaccine Laiv market size was estimated at USD 8569.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.30% during the forecast period.
This report provides a deep insight into the global Live Attenuated Influenza Vaccine Laiv market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Live Attenuated Influenza Vaccine Laiv Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Live Attenuated Influenza Vaccine Laiv market in any manner.
Global Live Attenuated Influenza Vaccine Laiv Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sanofi Pasteur_x000D_
AstraZeneca_x000D_
CSL_x000D_
Abbott_x000D_
GlaxoSmithKline_x000D_
Serum Institute_x000D_
Fluenz Tetra_x000D_
Cytiva_x000D_
BioDiem_x000D_
FluMist_x000D_
GSK_x000D_
ChangChun High & New Technology_x000D_
BCHT Biotechnology
Market Segmentation (by Type)
Trivalent Flu Vaccine_x000D_
Quadrivalent Flu Vaccine
Market Segmentation (by Application)
Hospital_x000D_
Clinic_x000D_
Public Health Agency_x000D_
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Live Attenuated Influenza Vaccine Laiv Market
Overview of the regional outlook of the Live Attenuated Influenza Vaccine Laiv Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine Laiv Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine Laiv, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
A Live Attenuated Influenza Vaccine (LAIV), also known as the ""nasal spray"" or ""intranasal"" flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.
The global Live Attenuated Influenza Vaccine Laiv market size was estimated at USD 8569.0 million in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.30% during the forecast period.
This report provides a deep insight into the global Live Attenuated Influenza Vaccine Laiv market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Live Attenuated Influenza Vaccine Laiv Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Live Attenuated Influenza Vaccine Laiv market in any manner.
Global Live Attenuated Influenza Vaccine Laiv Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Sanofi Pasteur_x000D_
AstraZeneca_x000D_
CSL_x000D_
Abbott_x000D_
GlaxoSmithKline_x000D_
Serum Institute_x000D_
Fluenz Tetra_x000D_
Cytiva_x000D_
BioDiem_x000D_
FluMist_x000D_
GSK_x000D_
ChangChun High & New Technology_x000D_
BCHT Biotechnology
Market Segmentation (by Type)
Trivalent Flu Vaccine_x000D_
Quadrivalent Flu Vaccine
Market Segmentation (by Application)
Hospital_x000D_
Clinic_x000D_
Public Health Agency_x000D_
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Live Attenuated Influenza Vaccine Laiv Market
Overview of the regional outlook of the Live Attenuated Influenza Vaccine Laiv Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine Laiv Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine Laiv, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
158 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine Laiv
- 1.2 Key Market Segments
- 1.2.1 Live Attenuated Influenza Vaccine Laiv Segment by Type
- 1.2.2 Live Attenuated Influenza Vaccine Laiv Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Live Attenuated Influenza Vaccine Laiv Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Live Attenuated Influenza Vaccine Laiv Market Size (M USD) Estimates and Forecasts (2020-2033)
- 2.1.2 Global Live Attenuated Influenza Vaccine Laiv Sales Estimates and Forecasts (2020-2033)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Live Attenuated Influenza Vaccine Laiv Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Live Attenuated Influenza Vaccine Laiv Product Life Cycle
- 3.3 Global Live Attenuated Influenza Vaccine Laiv Sales by Manufacturers (2020-2025)
- 3.4 Global Live Attenuated Influenza Vaccine Laiv Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Live Attenuated Influenza Vaccine Laiv Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Live Attenuated Influenza Vaccine Laiv Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Live Attenuated Influenza Vaccine Laiv Market Competitive Situation and Trends
- 3.8.1 Live Attenuated Influenza Vaccine Laiv Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine Laiv Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Live Attenuated Influenza Vaccine Laiv Industry Chain Analysis
- 4.1 Live Attenuated Influenza Vaccine Laiv Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Live Attenuated Influenza Vaccine Laiv Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Live Attenuated Influenza Vaccine Laiv Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Live Attenuated Influenza Vaccine Laiv Market
- 5.7 ESG Ratings of Leading Companies
- 6 Live Attenuated Influenza Vaccine Laiv Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Live Attenuated Influenza Vaccine Laiv Sales Market Share by Type (2020-2025)
- 6.3 Global Live Attenuated Influenza Vaccine Laiv Market Size Market Share by Type (2020-2025)
- 6.4 Global Live Attenuated Influenza Vaccine Laiv Price by Type (2020-2025)
- 7 Live Attenuated Influenza Vaccine Laiv Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Live Attenuated Influenza Vaccine Laiv Market Sales by Application (2020-2025)
- 7.3 Global Live Attenuated Influenza Vaccine Laiv Market Size (M USD) by Application (2020-2025)
- 7.4 Global Live Attenuated Influenza Vaccine Laiv Sales Growth Rate by Application (2020-2025)
- 8 Live Attenuated Influenza Vaccine Laiv Market Sales by Region
- 8.1 Global Live Attenuated Influenza Vaccine Laiv Sales by Region
- 8.1.1 Global Live Attenuated Influenza Vaccine Laiv Sales by Region
- 8.1.2 Global Live Attenuated Influenza Vaccine Laiv Sales Market Share by Region
- 8.2 Global Live Attenuated Influenza Vaccine Laiv Market Size by Region
- 8.2.1 Global Live Attenuated Influenza Vaccine Laiv Market Size by Region
- 8.2.2 Global Live Attenuated Influenza Vaccine Laiv Market Size Market Share by Region
- 8.3 North America
- 8.3.1 North America Live Attenuated Influenza Vaccine Laiv Sales by Country
- 8.3.2 North America Live Attenuated Influenza Vaccine Laiv Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Live Attenuated Influenza Vaccine Laiv Sales by Country
- 8.4.2 Europe Live Attenuated Influenza Vaccine Laiv Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Live Attenuated Influenza Vaccine Laiv Sales by Region
- 8.5.2 Asia Pacific Live Attenuated Influenza Vaccine Laiv Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Live Attenuated Influenza Vaccine Laiv Sales by Country
- 8.6.2 South America Live Attenuated Influenza Vaccine Laiv Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Live Attenuated Influenza Vaccine Laiv Sales by Region
- 8.7.2 Middle East and Africa Live Attenuated Influenza Vaccine Laiv Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Live Attenuated Influenza Vaccine Laiv Market Production by Region
- 9.1 Global Production of Live Attenuated Influenza Vaccine Laiv by Region(2020-2025)
- 9.2 Global Live Attenuated Influenza Vaccine Laiv Revenue Market Share by Region (2020-2025)
- 9.3 Global Live Attenuated Influenza Vaccine Laiv Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Live Attenuated Influenza Vaccine Laiv Production
- 9.4.1 North America Live Attenuated Influenza Vaccine Laiv Production Growth Rate (2020-2025)
- 9.4.2 North America Live Attenuated Influenza Vaccine Laiv Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Live Attenuated Influenza Vaccine Laiv Production
- 9.5.1 Europe Live Attenuated Influenza Vaccine Laiv Production Growth Rate (2020-2025)
- 9.5.2 Europe Live Attenuated Influenza Vaccine Laiv Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Live Attenuated Influenza Vaccine Laiv Production (2020-2025)
- 9.6.1 Japan Live Attenuated Influenza Vaccine Laiv Production Growth Rate (2020-2025)
- 9.6.2 Japan Live Attenuated Influenza Vaccine Laiv Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Live Attenuated Influenza Vaccine Laiv Production (2020-2025)
- 9.7.1 China Live Attenuated Influenza Vaccine Laiv Production Growth Rate (2020-2025)
- 9.7.2 China Live Attenuated Influenza Vaccine Laiv Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Sanofi Pasteur_x000D_
- 10.1.1 Sanofi Pasteur_x000D_ Basic Information
- 10.1.2 Sanofi Pasteur_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.1.3 Sanofi Pasteur_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.1.4 Sanofi Pasteur_x000D_ Business Overview
- 10.1.5 Sanofi Pasteur_x000D_ SWOT Analysis
- 10.1.6 Sanofi Pasteur_x000D_ Recent Developments
- 10.2 AstraZeneca_x000D_
- 10.2.1 AstraZeneca_x000D_ Basic Information
- 10.2.2 AstraZeneca_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.2.3 AstraZeneca_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.2.4 AstraZeneca_x000D_ Business Overview
- 10.2.5 AstraZeneca_x000D_ SWOT Analysis
- 10.2.6 AstraZeneca_x000D_ Recent Developments
- 10.3 CSL_x000D_
- 10.3.1 CSL_x000D_ Basic Information
- 10.3.2 CSL_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.3.3 CSL_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.3.4 CSL_x000D_ Business Overview
- 10.3.5 CSL_x000D_ SWOT Analysis
- 10.3.6 CSL_x000D_ Recent Developments
- 10.4 Abbott_x000D_
- 10.4.1 Abbott_x000D_ Basic Information
- 10.4.2 Abbott_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.4.3 Abbott_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.4.4 Abbott_x000D_ Business Overview
- 10.4.5 Abbott_x000D_ Recent Developments
- 10.5 GlaxoSmithKline_x000D_
- 10.5.1 GlaxoSmithKline_x000D_ Basic Information
- 10.5.2 GlaxoSmithKline_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.5.3 GlaxoSmithKline_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.5.4 GlaxoSmithKline_x000D_ Business Overview
- 10.5.5 GlaxoSmithKline_x000D_ Recent Developments
- 10.6 Serum Institute_x000D_
- 10.6.1 Serum Institute_x000D_ Basic Information
- 10.6.2 Serum Institute_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.6.3 Serum Institute_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.6.4 Serum Institute_x000D_ Business Overview
- 10.6.5 Serum Institute_x000D_ Recent Developments
- 10.7 Fluenz Tetra_x000D_
- 10.7.1 Fluenz Tetra_x000D_ Basic Information
- 10.7.2 Fluenz Tetra_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.7.3 Fluenz Tetra_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.7.4 Fluenz Tetra_x000D_ Business Overview
- 10.7.5 Fluenz Tetra_x000D_ Recent Developments
- 10.8 Cytiva_x000D_
- 10.8.1 Cytiva_x000D_ Basic Information
- 10.8.2 Cytiva_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.8.3 Cytiva_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.8.4 Cytiva_x000D_ Business Overview
- 10.8.5 Cytiva_x000D_ Recent Developments
- 10.9 BioDiem_x000D_
- 10.9.1 BioDiem_x000D_ Basic Information
- 10.9.2 BioDiem_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.9.3 BioDiem_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.9.4 BioDiem_x000D_ Business Overview
- 10.9.5 BioDiem_x000D_ Recent Developments
- 10.10 FluMist_x000D_
- 10.10.1 FluMist_x000D_ Basic Information
- 10.10.2 FluMist_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.10.3 FluMist_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.10.4 FluMist_x000D_ Business Overview
- 10.10.5 FluMist_x000D_ Recent Developments
- 10.11 GSK_x000D_
- 10.11.1 GSK_x000D_ Basic Information
- 10.11.2 GSK_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.11.3 GSK_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.11.4 GSK_x000D_ Business Overview
- 10.11.5 GSK_x000D_ Recent Developments
- 10.12 ChangChun High and New Technology_x000D_
- 10.12.1 ChangChun High and New Technology_x000D_ Basic Information
- 10.12.2 ChangChun High and New Technology_x000D_ Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.12.3 ChangChun High and New Technology_x000D_ Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.12.4 ChangChun High and New Technology_x000D_ Business Overview
- 10.12.5 ChangChun High and New Technology_x000D_ Recent Developments
- 10.13 BCHT Biotechnology
- 10.13.1 BCHT Biotechnology Basic Information
- 10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine Laiv Product Overview
- 10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine Laiv Product Market Performance
- 10.13.4 BCHT Biotechnology Business Overview
- 10.13.5 BCHT Biotechnology Recent Developments
- 11 Live Attenuated Influenza Vaccine Laiv Market Forecast by Region
- 11.1 Global Live Attenuated Influenza Vaccine Laiv Market Size Forecast
- 11.2 Global Live Attenuated Influenza Vaccine Laiv Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Live Attenuated Influenza Vaccine Laiv Market Size Forecast by Country
- 11.2.3 Asia Pacific Live Attenuated Influenza Vaccine Laiv Market Size Forecast by Region
- 11.2.4 South America Live Attenuated Influenza Vaccine Laiv Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Live Attenuated Influenza Vaccine Laiv by Country
- 12 Forecast Market by Type and by Application (2026-2033)
- 12.1 Global Live Attenuated Influenza Vaccine Laiv Market Forecast by Type (2026-2033)
- 12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine Laiv by Type (2026-2033)
- 12.1.2 Global Live Attenuated Influenza Vaccine Laiv Market Size Forecast by Type (2026-2033)
- 12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine Laiv by Type (2026-2033)
- 12.2 Global Live Attenuated Influenza Vaccine Laiv Market Forecast by Application (2026-2033)
- 12.2.1 Global Live Attenuated Influenza Vaccine Laiv Sales (K MT) Forecast by Application
- 12.2.2 Global Live Attenuated Influenza Vaccine Laiv Market Size (M USD) Forecast by Application (2026-2033)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
